TRANSCATHETER AORTIC VALVE REPLACEMENT IN ONCOLOGY PATIENTS WITH AORTIC STENOSIS

Patients with malignancy and severe aortic stenosis (AS) are often denied from surgical aortic valve replacement (AVR). Transcatheter AVR (TAVR) may be a better option for these patients, but was not yet systematically evaluated. An international TAVR in Oncology Patients with AS (TOP AS) registry